Literature DB >> 15767607

A man whose scapula was spared a drug-associated rash.

Alvaro Sanz1, María Luisa del Valle.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15767607      PMCID: PMC552886          DOI: 10.1503/cmaj.1040795

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  2 in total

1.  Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor.

Authors:  Mi-Woo Lee; Chul-Won Seo; Sang-We Kim; Hwa-Jeong Yang; Hae-Woong Lee; Jee-Ho Choi; Kee-Chan Moon; Jai-Kyoung Koh
Journal:  Acta Derm Venereol       Date:  2004       Impact factor: 4.437

2.  Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

Authors:  Masahiro Fukuoka; Seiji Yano; Giuseppe Giaccone; Tomohide Tamura; Kazuhiko Nakagawa; Jean-Yves Douillard; Yutaka Nishiwaki; Johan Vansteenkiste; Shinzoh Kudoh; Danny Rischin; Richard Eek; Takeshi Horai; Kazumasa Noda; Ichiro Takata; Egbert Smit; Steven Averbuch; Angela Macleod; Andrea Feyereislova; Rui-Ping Dong; José Baselga
Journal:  J Clin Oncol       Date:  2003-05-14       Impact factor: 44.544

  2 in total
  2 in total

1.  EMPACT syndrome: limited evidence despite a high-risk cohort.

Authors:  Andrew J Bishop; Maria Chang; Mario E Lacouture; Christopher A Barker
Journal:  J Neurooncol       Date:  2014-05-03       Impact factor: 4.130

2.  Irradiated fields spared Stevens-Johnson syndrome in a patient undergoing radiotherapy for bone metastases.

Authors:  Daniela Musio; Elisabetta Parisi; Francesco Dionisi; Giuseppe Parisi; Rossella Caiazzo; Nadia Bulzonetti; Miriam Lichtner; Nicola Raffetto; Vincenzo Vullo; Enzo Banelli
Journal:  Jpn J Radiol       Date:  2009-03-12       Impact factor: 2.374

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.